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Abstract
Background: Multiple studies concluded that oncometabolites (e.g. D-2-hydroxyglutarate (2-HG) related to mutant
isocitrate dehydrogenase 1/2 (IDH1/2) and lactate) have tumour promoting potential. Regulatory mechanisms
implicated in the maintenance of oncometabolite production have great interest. mTOR (mammalian target of
rapamycin) orchestrates different pathways, influences cellular growth and metabolism. Considering hyperactivation
of mTOR in several malignancies, the question has been addressed whether mTOR operates through controlling of
oncometabolite accumulation in metabolic reprogramming.
Methods: HT-1080 cells – carrying originally endogenous IDH1 mutation – were used in vitro and in vivo. Anti-
tumour effects of rapamycin were studied using different assays. The main sources and productions of the
oncometabolites (2-HG and lactate) were analysed by 13C-labeled substrates. Alterations at protein and metabolite
levels were followed by Western blot, flow cytometry, immunohistochemistry and liquid chromatography mass
spectrometry using rapamycin, PP242 and different glutaminase inhibitors, as well.
Results: Rapamycin (mTORC1 inhibitor) inhibited proliferation, migration and altered the metabolic activity of IDH1
mutant HT-1080 cells. Rapamycin reduced the level of 2-HG sourced mainly from glutamine and glucose derived
lactate which correlated to the decreased incorporation of 13C atoms from 13C-substrates. Additionally, decreased
expressions of lactate dehydrogenase A and glutaminase were also observed both in vitro and in vivo.
Conclusions: Considering the role of lactate and 2-HG in regulatory network and in metabolic symbiosis it could
be assumed that mTOR inhibitors have additional effects besides their anti-proliferative effects in tumours with
glycolytic phenotype, especially in case of IDH1 mutation (e.g. acute myeloid leukemias, gliomas, chondrosarcomas).
Based on our new results, we suggest targeting mTOR activity depending on the metabolic and besides molecular
genetic phenotype of tumours to increase the success of therapies.
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Background
Mammalian target of rapamycin (mTOR) kinase repre-
sents an important regulator of cellular metabolism
besides of its effects on cellular growth, protein synthe-
sis, proliferation and survival. mTOR senses energy sup-
ply, nutrients, growth factors and other conditions in
tumour microenvironment (e.g. oxygen, stress) at the
crossroad of cellular signalling networks [1–3]. Available
energy and nutrients besides appropriate growth factors
allow mTOR activity which supports anabolic pathways,
however, the absence of the above mentioned factors
leads to the inactivation of mTOR and inhibits the anabol-
ism and induces the cellular catabolism, such as autoph-
agy. mTOR complexes orchestrate different pathways and
based on their input influence cellular growth and meta-
bolic programs. mTOR kinase exists in two structurally
and functionally different protein complexes: rapamycin
sensitive mTORC1 and rapamycin-resistant mTORC2
(however, mTORC2 could be rapamycin sensitive during
a long-term treatment) [4, 5]. The multiple regulatory
functions of mTOR complexes are achieved through
different downstream targets. Translation, ribosome and
mitochondrial biogenesis, autophagy, lipid biosynthesis
are controlled by mTORC1, which phosphorylates e.g.
p70S6K and 4-EBP1 and consequently other targets such
as S6 which is a well-known marker of mTORC1 activity
at protein level. mTORC2 phosphorylates e.g. Akt (at
S473), SGK1 and PKCα and enhances survival and
cytoskeletal reorganization [3]. Data about other func-
tions of mTORC2 are emerging e.g. a potential meta-
bolic regulatory role of mTORC2 is also in the centre
of interest in recent studies.
The failures in PI3K/Akt/mTOR signalling pathway and
hyperactivated mTOR kinase have been described in
many tumours. In fact, a correlation between elevated
mTOR activity – especially with potential high
mTORC2 activity (mTORC2 complex related Rictor
overexpression) – and poor clinical prognosis of dif-
ferent malignancies has been previously described in
our and other studies [6–8]. Rapamycin (mTORC1 in-
hibitor) and its analogues (rapalogs; e.g. temsirolimus,
everolimus) have been approved by FDA (Food and
Drug Administration) and EMA (European Medicines
Agency) in certain lymphomas, renal cell carcinomas,
pancreatic and breast cancers; rapalogs and newly de-
veloping inhibitor phase studies are ongoing in many
other malignancies.
The regulatory role of mTOR activity in the metabolic
reprogramming has been highlighted in recent years.
mTORC1 complex activity is necessary for appropriate
glycolysis, glutamine consumption, pentose-phosphate
pathway, lipid and nucleotide synthesis; moreover, it
downregulates autophagy [9–11]. Through regulating
these mechanisms, mTOR activity can help the adaptation
to altered energy-, nutrient supplies and microenviron-
ment in metabolic reprogramming [12–14].
Lactate production is a result of Warburg effect in
different tumours [10, 15]. Lactate can be regarded as an
oncometabolite – oncometabolites are defined as small-
molecule components of normal metabolism of which
accumulation causes signalling dysregulation to establish
a milieu that initiates carcinogenesis – based on emer-
ging data. Lactate contributes to many effects which
help the survival and clonal evolution of resistant
tumour cells in tissue microenvironment [16–18]. The
tumour microenvironment is a complex network of
extracellular matrix molecules, soluble factors, non-
tumorous cells, including stromal (e.g. cancer associated
fibroblasts and endothelial cells, adipocytes) and immu-
noregulatory cells. Among the soluble factors present in
the microenvironment, lactate production has particular
importance through its effects not only in cancer, but
also, in neighbouring cells. In vivo lactic acid contributes
to acidosis, which – besides triggering pain in cancer
patients – has more important signals for tumour angio-
genesis and tumour immunosuppression, as well [19]. In
addition, the decreasing pH may contribute to the
metastasis formation (e.g. through MMP activation,
matrix remodelling) of some cancers [19].
Moreover, tumour and stromal cells can utilize lactate
for energy production depending on the oxygen concen-
tration in metabolic symbiosis, as well [20, 21]. Certain
dysfunctioning metabolic enzymes – e.g. mutated FH,
SDH or IDH (mitochondrial IDH2 or cytoplasmic IDH1)
– promote the accumulation of other oncometabolites
such as fumarate, succinate and D-2-hydroxyglutarate
[17, 22]. 2-hydroxyglutarate could exist as L- or D-
enantiomers. Low level of L-2-HG could be produced
independently from mutant IDH activity in certain cells
at hypoxic conditions (e.g. malate dehydrogenase).
However, D-2-HG (2-HG) is generated from α-KG by
the mIDH and the level of this oncometabolite is highly
elevated in mIDH bearing malignant cells [23].
The role of different oncometabolites is intensively
studied in many tumourigenic events (pseudohypoxia,
DNA methylation, histone modification etc.) and bio-
energetics of tumour cells. Moreover, the expected
regulatory role of 2-HG was also concluded in repro-
gramming of normal stromal cells, which could have
tumour promoting effects on the microenvironment, as
well [24]. IDH1 mutations are described in 80% of gli-
omas, 20% of acute myeloid leukemias (AMLs) and in
certain cholangiocarcinomas, thyroid cancers and chon-
drosarcomas [23, 25]. There are no data available about
the role of mTOR activity in 2-HG production in any
homozygous or heterozygous IDH mutant cells. Con-
sidering the aberrant regulatory impact of mTOR in
malignant cells the question has been addressed whether
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mTORC1 operates through controlling of oncometabo-
lite accumulation in metabolic reprogramming.
In the present work, a heterozygous IDH1 mutant cell
line and its rapamycin sensitivity were studied in vitro
and in vivo. Our new results proved the role of mTOR
activity and the inhibitory effect of rapamycin both in
lactate and in 2-HG oncometabolite productions of
heterozygous IDH1 mutant fibrosarcoma cells.
Methods
All materials were purchased from Sigma-Aldrich,
except where it is indicated in the text.
In vitro cell cultures and different treatments
HT-1080 endogenous heterozygous IDH1 mutant cell
line was used for both in vitro and in vivo experiments.
HT-1080 (CCL121-ATCC); KMH2, DEV (human Hodgkin
lymphoma cells purchased from DSMZ), ZR-75.1
(CRL-1500-ATCC), U251 MG homozygous IDH1-
R132H mutant (kindly provided by prof. W. Leenders)
[26]) cells were cultured in RPMI 1640 (R8758) or
DMEM high glucose (Biosera, LM-D1108) (for U251
MG) medium supplemented with 10% (20% for DEV)
fetal bovine serum (Hyclone) and gentamycin (for U251
MG penicillin-streptomycin). For different measure-
ments, we plated the cells into T25 or T75 flasks (for
Western blot, LC-MS and 13C-labelling experiments) or
onto 6-, 96-well plates (for flow cytometry and Alamar
Blue proliferation tests) using appropriate cell numbers
(3-8×105 cells/flask or 2-50×103 cells/well). Cells were
treated with rapamycin (0.01–200 ng/mL), PP242
(1 μM, Tocris), BPTES (10 μM), Zaprinast (1-100-
300 μM), sodium-L-lactate (5 mM), sodium D-2-
hydroxyglutarate (0.5 mM) for 24–72 h. In 13C-labelling
metabolic experiments, the plated cultures were washed
(with DMEM D5030 – glucose-, glutamine- and
pyruvate-free medium) and the medium was replaced
by DMEM D5030 medium during labelling.
For 13C-labelling cells were incubated with 10 mM
U-13C-glucose or 4 mM U-13C-glutamine or 10 mM
2-13C-acetate (Cambridge Isotope Laboratories, Andover,
MA, USA) in D5030 medium for one hour before
the extraction.
Cell proliferation, apoptosis and migration assays
To analyse the proliferation capacity Alamar Blue test
was used (Thermo Fisher Scientific) – the incubation
period was 4 h. Fluorescence was measured by Fluoros-
can Ascent FL fluorimeter software (Labsystems Inter-
national). Percentage of proliferation was given relative
to control samples.
Apoptosis and cell cycle were measured by SubG1
analysis as described by Nagy et al. [27]; 106 cells were
fixed in ice-cold ethanol (70%), followed by alkaline
extraction (200 mM Na2HPO2, pH 7.4), then stained
with propidium-iodide. The measurements were carried
out with FACSCalibur (BD Biosciences) and analysed by
Kaluza software (Beckman Coulter).
Vertical migration from monolayer into extracellular
matrix (ECM; MAXGel ECM) gel was studied using
untreated and rapamycin treated (48 h, 50 ng/mL) HT-
1080 cells (5×104) in six-well micro-plates and then
ECM was overlaid and the tumour cells were allowed to
migrate into the gel in the next 24 h. At the end of the
incubation period the ECM gel was removed from the
monolayer, the cells were released from both compart-
ments and were counted in hemocytometer. The migra-
tory capacity was given in the percentage of the cells
which migrated into the matrix after rapamycin treat-
ment related to the controls [28].
Expression analysis of different proteins by Western blot
and flow cytometry
For Western blot analysis protein extracts from lysated
cells were quantitated using Quant-iT protein assay
(Invitrogen) and were separated by SDS-PAGE. Proteins
were transferred to PVDF membrane applying semidry
technique (BioRad), membranes were incubated with the
following antibodies: anti-phospho-mTOR (Ser2448,
1:1000, #2971; Cell Signaling Technologies – CST), anti-
phospho-S6 (Ser 235/236, 1:1000, #2211; CST), anti-
Rictor (1:1000, #2140; CST), anti-Raptor (1:500, #89603;
Novus), anti-mTOR (1:1000, #2938; CST), anti-S6 (1:1000,
#2317; CST), anti-lactate dehydrogenase A (LDH-A)
(1:1000; #3582, Cell Signaling), anti-glutaminase (Gls)
(1:1000; #15676, Abcam) and anti-β-actin (1:5000; #A228,
Sigma-Aldrich) as loading control. Finally, biotinylated
secondary antibodies, avidin-HRP complex (Vectastain
Elite ABC Kit, Vector) and enhanced chemiluminescence
technique (Pierce ECL Western Blotting Substrate using
Kodak-Xmat) were used.
For flow cytometric measurements 106 cells were fixed
and permeabilized using IntraStain Kit (DAKO), then
were stained with the appropriate primary antibodies
anti-LDH-A (1:200; #3582, Cell Signaling), anti-Gls
(1:250; #15676, Abcam) after different treatments. LDH-
A and Gls expressions were detected with secondary
anti-rabbit IgG Alexa-Fluor 647 antibody (Invitrogen).
Samples were measured by Navios flow cytometer
(Beckman Coulter) and analysed by Kaluza software
(Beckman Coulter). Displayed results are mean fluores-
cence intensities (MFI).
Confirmation of IDH mutation by Sanger sequencing
Both IDH1 and IDH2 genes were analysed after using
routine DNA Isolation kit for Cells and Tissue
(Roche), specific amplifications (AmpliTaqGold Master
Mix with the appropriate primers - IDH1 exon4 forward:
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aaaactttgcttctaatttttctcttt; reverse: acatacaagttggaaatttctgg,;
IDH2 exon4 forward: tctagactctactgccttcctc; reverse: gtca
gtggatcccctctcca – AppliedBiosystems), purification (Exo-
SAP-IT – Affimetrix) and direct sequencing (25 cycles at
51 °C, BigDye 3Terminator v3.1 Cycle Sequencing Kit in
Genetic Analyser 3500 - Applied BioSystem).
Metabolite analysis using liquid chromatography mass
spectrometry
Intracellular metabolites (lactate, citrate, malate, succin-
ate, 2-HG) were extracted by a modified method based
on Szoboszlai et al. [29]. In brief, the cells were
quenched in liquid nitrogen and extracted by mixture of
MeOH–chloroform–H2O (9:1:1) and vortexed at 4 °C.
After centrifugation (15,000xg, 10 min, 4 °C) the clear
supernatants were kept at −80 °C. The samples were
prepared for LC-MS by the established derivatization
based on the protocol of Jaitz et al. [30]. For derivatiza-
tion 3-nitrobenzyl-alcohol + trimethyl-chlorsilane were
added to the dried samples, sonicated and incubated at
80 °C for 45 min. The reaction was stopped by 100 mM
ammonium-hydrogencarbonate solution. After these
processes the samples were diluted in acetonitrile-water
solution. Gradient elution was used with reversed-phase
chromatography in Waters Acquity LC system. The
detection was performed by Waters Micromass Quattro
Micro triple quadrupole mass spectrometer (Waters
Corporation, Milford MA, USA) using electrospray
source in the positive ion mode with single ion monitor-
ing mode. Standards (L-lactic acid, L-malic acid, succinic
acid, citric acid, D-2-hydroxyglutarate) and other chemi-
cals except for labelled substrates were purchased from
Sigma-Aldrich for these measurements. The analytes
were detected in multiple reaction monitoring mode in
MS. HT-1080 cells produce only D-2-HG [31]. Applying
this method, we did not distinguish L- and D- 2-HG
enantiomers and we use 2-HG, as a synonym for D-2-
HG in the manuscript.
For 13C-labelling, cells were incubated with 10 mM
U-13C-glucose or 4 mM U-13C- glutamine or 10 mM
2-13C-acetate (Cambridge Isotope Laboratories, Andover,
MA, USA) in D5030 medium for one hour before the
extraction.
In vivo studies with HT-1080 xenograft model
Xenograft tumours were established in SCID mice by
injecting 2 × 106 HT-1080 cells subcutaneously (s.c.) into
the sole region of 8–10-week-old (20–23 g) mice.
Palpable tumours were removed and cut into equal
pieces then were transplanted into secondary recipient
mice. When palpable s.c. tumours developed, animals
were divided into control and rapamycin-treated groups
(n = 10 each). Rapamycin (Rapamune 1 mg/mL, Wyeth
Europa Ltd.) was administered by gavage at 3 mg/kg
body weight three times per week for 3 weeks. Control
groups were treated with saline. Body weight and
tumour size were determined. Tumour volume was
calculated as follows: п/6 × (2 × shorter diameter + longer
diameter)/3)3. Tumour weights were measured in eutha-
nized animals at the end of the experiments. Tumour
tissues were formalin-fixed and paraffin-embedded.
Immunostaining was performed by anti-p-S6 (1:100;
#2211; CST), anti-p-mTOR (1:100; 2971, CST), anti-Gls
(1:200, #15676, Abcam) and anti-LDH-A (1:400; #3582,
CST) antibodies according to Krencz et al [32]. Frozen
tumour samples were also preserved at -80 °C for
LC-MS metabolite extraction. In vivo experiments
were approved by the Institutional Ethical Review
Board (PEI/001/2457-6/2015) and the Institutional
Animal Care Laboratory, with official permissions
(PEI/001/1733-2/2015).
Statistical analysis
The data are presented as mean ± standard deviation
and calculated from three independent experiments with
minimum three or more parallels, depending on the
used method. Data evaluation was performed using
Student’s t (two-tailed) test and variance analysis
(ANOVA) for multiple comparisons with PAST 3.05
software. p < 0.05 was considered statistically significant.
Results
The source of elevated oncometabolite levels (lactate and
2-HG) in IDH1 mutant HT-1080 cells
Characterising the dominant bioenergetic process in HT-
1080 fibrosarcoma cells increased glycolysis and impaired
TCA (tricarboxylic acid) cycle were observed in our previ-
ous study [33]. 2-HG production (Fig. 1a) – high level of
this oncometabolite was detected by LC-MS – and the
decreased number and irregular arrangement of the cris-
tae in mitochondria (electron microscopy-data not shown)
represent other remarkable properties of HT-1080 cells.
To elucidate the involvement of IDH1 in the enhanced
production of 2-HG the exons of IDH1 gene were
sequenced. Heterozygous IDH1 gene mutation (R132C)
was confirmed by Sanger sequencing in the studied HT-
1080 cells (Fig. 1b).
High levels of lactate (~27 nmol/106 cells) and 2-HG
(~18 nmol/106 cells) regarded as oncometabolites were
characteristic features of HT-1080. The sources of the
produced oncometabolites were studied after using
different 13C labelled substrates (glucose, glutamine,
acetate) and LC-MS. Incorporation of 13C atoms was
shown in ~16% of lactate after one-hour 13C glucose
labelling in HT-1080 cultures. However, neither U-13C
glutamine nor 2-13C acetate could label lactate in these
cells. Low level of 13C labelling from glucose was
detected in 2-HG (~6% of total 2-HG pool), as well.
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Acetate substrate could not label 2-HG. However, glu-
tamine was proved to be a remarkable source (~15%) of
2-HG (Fig. 1c).
Rapamycin inhibited mTOR related protein expression,
cell proliferation and migration of HT-1080 cells
The role of the described high mTORC1 activity [33]
was studied in our work by rapamycin (mTORC1 inhibi-
tor) treatment. Dose dependent anti-proliferative effect
(0.1–200 ng/mL) of rapamycin was tested in vitro; based
on the evaluation of our and other published results
50 ng/mL was selected for further in vitro studies. Both
Alamar Blue test and the evaluation of cell number con-
firmed the time dependent effect (Fig. 2a) of 50 ng/mL
rapamycin, as well. These were supported by flow cy-
tometry, however, apoptotic effect was not detected after
rapamycin treatment in these IDH1 mutant cells after
24–72-h treatment (data not shown). The migration of
HT-1080 cells was also inhibited after rapamycin treat-
ment in ECM gels, the number of the migrated cells was
reduced by more than 80%. Rapamycin sensitivity was
confirmed after 48-h treatment by Western blot (Fig. 2b).
Densitometric analysis showed significantly decreased
expression in phosphorylated forms of S6 and mTOR
(more than 85% decreasing in both p-S6 and p-mTOR,
besides the total level of S6 and mTOR did not change).
In parallel, Raptor and Rictor expressions were also
reduced.
Rapamycin decreased lactate and 2-HG oncometabolite
production by reducing the amount of LDH-A and
glutaminase enzymes
Significantly decreased intracellular levels of lactate and
2-HG were detected using LC-MS measurements after
in vitro rapamycin treatment (Fig. 3a, b). Rapamycin
altered the levels of various TCA cycle intermediates, as
well; however, these changes were not proved to be
significant (Fig. 3c). The effect of the remaining 2-HG
and lactate levels in parallel with 48-72-h rapamycin
treatment were also tested in vitro by adding 2-HG and/
or lactate. In our experimental systems, we could not
observe significant influences of lactate and/or 2-HG in
proliferation, in growth potential and in rapamycin sen-
sitivity of HT-1080 cells (Additional file 1: Figure S1.).
The metabolic effect was verified by using one-hour
13C-substrate labelling after 48-h rapamycin treatment
and measuring-evaluating unlabelled and labelled me-
tabolite levels by LC-MS. 13C atoms appeared in 16% of
a
c
b
Fig. 1 Consequence of IDH1 mutation in HT-1080. The detected 2-HG peak on chromatogram (LC-MS) (a.) and the heterozygous IDH1 gene
mutation which resulted IDH1 R132C was confirmed by sequencing (Sanger) (b.); The main sources of 2-HG production were evaluated by 13C
incorporations in 2-HG after one-hour U-13C-glucose or U-13C-glutamine labelling and LC-MS (representative data) (c.). tr: retention time;
m + 0 = unlabelled metabolites; m + 1/2/3 = 1/2/3 13C in 2-HG from glucose, m + 5 = 5 13C in 2-HG from glutamine, (m + 4 and m + 5
isotopomers were not detectable in these cells after one-hour glucose labelling in 2-HG)
Hujber et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:74 Page 5 of 12
Fig. 2 In vitro effects of rapamycin in HT-1080 cells (anti-proliferative effect and the decreased expressions of mTOR activity related proteins). The
anti-proliferative effect of rapamycin was confirmed by Alamar Blue test after 4-24-48-72-h (the results of a representative experiment
n = 6, *:p < 0.05) (a.). Reduced expressions of mTOR kinase activity related proteins (p-S6 and p-mTOR) were shown after 48-h rapamycin
(50 ng/mL) treatment by Western blot analysis (representative blot) Co = control; R = rapamycin (b.)
a b c
d e f
Fig. 3 Rapamycin treatment reduced lactate and 2-HG productions in vitro (LC-MS measurements). The relative levels of lactate and 2-HG (a.); the
levels of these oncometabolites in nmol/106 cells (b.); the relative levels of succinate, malate and citrate (c.) after 48-h rapamycin treatment (50 ng/mL);
The changes in relative level of total lactate (m+ 0 and m+ 3) were shown after 48-h rapamycin treatment and one-hour U-13C-glucose labelling (d.);
The reduced level of total 2-HG (m+ 0 and m+ 1/2/3) was also detected after rapamycin treatment and U-13C-glucose labelling (e.) or U-13C-glutamine
substrate labelling (f.) m + 0 = unlabelled metabolites; m + 3 = 3 13C in lactate from glucose, m + 1/2/3 = 1/2/3 13C in 2-HG from glucose,
m + 5 = 5 13C in 2-HG from glutamine, (m + 4 and m + 5 isotopomers were not detectable in these cells after one-hour glucose labelling
in 2-HG); Levels of metabolites were expressed relative to the control (control level = 1) and the tables show the absolute levels of
labelled and unlabelled metabolites after rapamycin treatment. (n = 3, *:p < 0.05;)
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lactate from U-13C-glucose in control HT-1080 cells at
these experimental conditions. 48-h rapamycin treat-
ment reduced the level of total lactate (both 12C- and
13C-lactate) by more than 50% and blocked the incor-
poration of 13C from U-13C-glucose into lactate using
one-hour labelling period at the end of the treatments
(Fig. 3d). 2-HG production was also reduced effectively
after rapamycin treatment, U-13C-glucose and U-13C-
glutamine labelling studies confirmed that rapamycin
inhibited 2-HG production. The total level of 2-HG was
reduced by more than 75% and the amount of 13C-labelled
2-HG was also reduced significantly after using either
glucose or glutamine labelling in one-hour time period in
the treated cells compared to controls (Fig. 3e, f ).
The regulatory role of mTORC1 activity in both LDH-
A and glutaminase expressions were analysed by flow
cytometry in these experiments. Rapamycin reduced the
expression of LDH-A and glutaminase at protein levels
in HT-1080 cells after 48-h treatment (Fig. 4a, b). These
were further confirmed by Western blot, as well
(Fig. 4c). The role of glutaminase enzyme activity in
2-HG production was proved by Zaprinast and BPTES
treatments in HT-1080 cells. Similar to rapamycin, Zapri-
nast and BPTES could also reduce 2-HG production
(Fig. 4d). This was occurred at enzyme activity level [34],
as glutaminase inhibition did not influence the protein
expression of glutaminase negatively (data not shown).
Zaprinast also reduced the proliferation of HT-1080 cells
a b
c d
e f
Fig. 4 mTOR inhibitors (rapamycin, PP242) decreased the expressions of LDH-A and glutaminase proteins in HT-1080 cells; and glutaminase
inhibitors (Zaprinast, BPTES) have effects on both the proliferation and the 2-HG oncometabolite level in these cells. LDH-A and Gls expressions
were significantly reduced after 48 h rapamycin (50 ng/ml) and PP242 (1 μM) treatment (a. and b. show flow cytometric results, X-Gmean
average ± SD n = 3,*:p < 0.05; c. Western blot). The effects of mTOR and glutaminase inhibitors on the 2-HG production and proliferation (d.)
(Alamar Blue test; Rapa.: rapamycin 50 ng/mL; PP242: 1 μM; Zap.: Zaprinast 100 μM; BPTES: 10 μM). The effect of rapamycin and Zaprinast on the
2-HG production (e.) (LC-MS using U-13C-glutamine labelling; n = 3, levels of metabolites were expressed relative to the control (control level = 1),
m + 0 = unlabelled 2-HG; m + 5 = 5 13C in 2-HG, n.d.: not detected; *:p < 0.05). The results of Alamar Blue test after using 48-h Zaprinast and
rapamycin (50 ng/ml) combination treatments in HT-1080 cells (f.)
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in vitro (Fig. 4e, f ). However, rapamycin was significantly
more effective than Zaprinast after 48–72-h treatment.
Moreover, rapamycin and Zaprinast showed no additive ef-
fect on proliferation, this combination was not more effect-
ive than rapamycin alone (Fig. 4f).
To exclude non-target effect of rapamycin, as a chemical
compound, we used an other mTOR inhibitor (PP242)
and compared their effects on 2-HG, lactate production
and on LDH-A, Gls protein expression and on prolifera-
tion, as well. PP242 is an ATP-competitive compound,
which is highly selective to mTOR kinase in both
mTORC1 and C2 complexes; it is a non-FKBP12 binding
drug as mTORC1 inhibitor rapamycin. In addition, PP242
has similar effects on proliferation, Gls and LDH-A
protein level (Fig. 4c, d), in parallel PP242 reduced the
lactate level near to 60%, the 2-HG level near to 40%.
These suggest that the inhibition of mTOR kinase is
involved in the alteration of these parameters.
The lactate production of highly glycolytic other non-
IDH mutant cell lines were also tested after in vitro
rapamycin treatment in two human Hodgkin lymphoma
cells and in another previously metabolically charac-
terised ZR-75.1 human breast carcinoma cell line. 48–
72 h rapamycin treatment could reduce the amount of
lactate in these cells; the unlabelled lactate levels were
significantly reduced to 85%–65% (DEV-75%, KMH2-
85%, ZR-75.1–65%) in these other malignant cells. The
use of one-hour U-13C-glucose labelling at the end of
rapamycin treatments could confirm these changes, the
labelled 13C-lactate level decreased to 30% in DEV and
near to undetectable level in the other two cell lines in
our experiments. Furthermore, we have chance to ana-
lyse 2-HG production of a generated (genetically modi-
fied) homozygous IDH1 mutant glioma cell line – U251
MG. In these cells, we detected high 2-HG production
(~24 nmol/106 cells), however, the known low glycolytic
capacity of this kind of glioma cells was also observed.
The elevated 2-HG and proliferation levels were signifi-
cantly reduced (near to 75% and 80%, respectively) after
48-h mTOR inhibitor treatment which confirmed our
findings about the 2-HG reducing effect of rapamycin
treatment in other 2-HG producing tumour type, in
glioma cells.
Rapamycin inhibited the growth and the oncometabolite
production in HT-1080 xenografts in vivo
The in vivo inhibitory effect of mTORC1 inhibitor Rapa-
mune (oral rapamycin drug) on tumour growth was also
confirmed in HT-1080 xenotransplanted SCID mice.
Rapamune treatment significantly reduced tumour
weights and tumour volumes in vivo (Fig. 5a, b). The in
vivo inhibitory effect of the applied treatment on mTORC1
activity and on the expression of Gls and LDH-A were con-
firmed by using p-S6, p-mTOR, Gls and LDH-A
immunostainings (Additional file 2: Figure S2.). The sig-
nificantly reduced oncometabolite levels – lactate and 2-
HG – were also detected by LC-MS in frozen tumour
tissues of HT-1080 xenografts (Fig. 5c, d).
Discussion
Several studies have shown that metabolic intermediates
have potential to modulate oncogenic (including cellular
and extracellular mechanisms) and epigenetic processes.
Moreover, the accumulation of certain metabolites with
normal or altered structures – designated as oncometa-
bolites – may contribute to carcinogenesis in many
aspects [35, 36].
Noteworthy, oncometabolites are interconnected and
form a network to act by cooperative or autoregulated
manner in tumourigenesis, as well [35–38]. Recently,
Kottakis et al. have supported this network concept es-
pecially at epigenetic level in correlation with the func-
tions of mTOR controlled pathways [39]. This work
underlines the importance of our new data about mTOR
activity dependent regulation of lactate and 2-HG pro-
ductions in mIDH1 HT-1080 fibrosarcoma. The pre-
sented data showed that mTOR complex inhibitors – in
parallel reduce tumour growth and migration – have sig-
nificant inhibitory effect on the productions of both
glycolytic lactate and mainly from glutamine sourced 2-
HG oncometabolites in vitro and in vivo. According to
our results and the known microenvironmental tumour
promoting effects of tumour derived lactate, not only
the well-known anti-proliferative effect of mTOR inhibi-
tors should be considered. The altered levels of oncome-
tabolites, especially their potential extracellular effects
should also be taken into account in case of starting to
use rapalog treatments. For example, doxorubicin in-
hibits the proliferation, however, it could not signifi-
cantly alter the studied oncometabolite levels in HT-
1080 cells (data not shown, unpublished results). The re-
duction of lactate and 2-HG oncometabolites could have
fewer effects on stable tumour cell lines in short-term
treatments than in their microenvironment and in
the associated inflammatory or other “normal” (non-
tumour) cells at tissue level. The reduced levels of
oncometabolites are interesting for further studies because
rapamycin preferentially reduced the productions of lac-
tate and 2-HG relative to succinate, malate and citrate.
Our observations call the attention to the translational
effects of mTOR activity [37, 40], which were proved by
the detected decrease of LDH-A and Gls expressions at
protein level both in vitro and in vivo (Fig. 6.).
As far as the regulatory role of mTOR in protein
translation is concerned, there are only limited data
about mTOR hyperactivity dependent metabolic alter-
ations related to oncometabolite productions, especially
2-HG. The detected correlation between hyperactivated
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Fig. 5 The effects of rapamycin on tumour growth and on oncometabolite production in vivo. Growth curve of the tumour (a.), and the
measured tumour weights (b.), lactate (c.) and 2-HG (d.) levels of control and Rapamune (3 mg/kg, 3 weeks) treated HT-1080 xenografts (LC-MS,
n = 6,*:p < 0.05; metabolite levels in nmol/10 mg tumour mass were given
Fig. 6 The effect of rapamycin on metabolic profile of IDH1 mutant HT-1080 cells. Rapamycin treatment reduced the levels of two
oncometabolites in parallel - lactate and 2-HG - in high glycolytic, IDH1 mutant fibrosarcoma cells. mTOR inhibition decreased metabolic
capacity, the glycolysis and the glutaminolysis with remarkable downregulation of LDH-A and glutaminase enzyme expressions in HT-1080
cells (further explanation in the discussion)
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mTOR and LDH expressions and the related lactate pro-
duction corresponds to the known regulatory role of
mTOR activity in the expressions of glycolytic enzymes
[41, 42]. Various interactions between mTOR activity
and metabolic alterations including oncometabolite pro-
duction have been studied in few available reports ap-
plying different experimental conditions. It has been
reported that 2-HG could equally activate and inhibit
mTOR in different cells (genetically manipulated glio-
blastoma, C. elegans etc.) [43, 44]. Since different bio-
logical systems have been used in these experiments,
there is a possibility that the outcome of 2-HG action
has been influenced by different modulators such as
origin and timing of their presence. However, these an-
tagonistic impacts between oncometabolites and mTOR
activity may suggest a possible coordination of lactate
and 2-HG for joint tumour promoting functions. Never-
theless, it is noteworthy that our conclusion based on
the obtained results – with an established primarily het-
erozygous mutant IDH1 fibrosarcoma cell line – are in
harmony with those reported by Carbonneau et al [44].
Their results have demonstrated mTOR kinase activa-
tion in other models in different tumour cells (HeLa,
immortalized astrocytes) after octyl-2-HG treatment or
in newly mIDH transfected cells.
Herein we confirmed their findings that mIDH can
lead both to 2-HG production and to aberrant activation
of mTOR kinase [44] using other primarily endogenous
heterozygous IDH1 mutant cell line. However, our new
findings provide that the hyperactivity of mTOR kinase
is needed to produce 2-HG in the studied primarily
IDH1 mutant cells.
Nevertheless, the presented data support our view that
the detected reductions at different oncometabolite
levels correlate to the inhibited proliferation, migration
after rapamycin treatment in HT-1080 cells in vitro. The
detected decrease of mTOR activity and its correlation
with diminished oncometabolite level and tumour
growth were also demonstrated in vitro xenografts in
our study. This effect of rapamycin treatment highlights
the importance of mTOR activity in malignant pheno-
type of IDH1 mutant cells. Our results – concerning the
potential roles of mTOR activity and 2-HG production
in migration of malignant cells – confirm the recently
published data about the enhanced migration capacity of
mIDH1 transfected glioma cells [45]. Only this study
and our work show the potential benefit of mTOR
inhibitors on the migration of IDH mutation related
malignant cellular phenotype, in this context.
The anti-tumour effects of rapalogs, other mTOR in-
hibitors and elevated mTOR activity have been de-
scribed previously in many tumours including gliomas,
AMLs and chondrosarcomas (where the occurrence of
the IDH mutation is remarkable) [46]. Rapalogs and
newly developed mTOR inhibitors are being tested with
recurrent and therapy resistant malignancies, especially
in AML and glioma patients [47–49].
Based on our recent findings and the emerging data
about the relation between high mTOR activity and IDH
mutation, we also highlight the importance of recently
ongoing and future studies in different AMLs, gliomas,
and sarcomas. We also suggest studying the metabolic
profile, IDH status or oncometabolite productions – e.g.
lactate and 2-HG level – in these patients. Our results
showed that the endogenous mutant IDH1 expressing
HT-1080 fibrosarcoma cells with glycolytic phenotype
proved to be a suitable model to characterise the role of
mTOR in the regulation of 2-HG and lactate produc-
tions. The present study provided evidence for the
first time for simultaneous reduction of two onco-
metabolites (lactate and 2-HG) by mTOR inhibitor.
Moreover, we could detect such a reducing effect of
rapamycin in oncometabolite level, especially in glyco-
lytic lactate production in other lymphoma and breast
cancer cells.
Other laboratories – with separate studies on either
lactate or 2-HG expression– have described that specific
glycolysis or glutaminolysis inhibitors (such as deoxyglu-
cose or Zaprinast, BPTES) can reduce the cellular prolif-
eration in vitro, however, they have no significant
efficacy in vivo in monotherapy [34, 50, 51]. The mTOR
inhibitors (rapamycin mTORC1 and PP242 C1-C2
inhibitors) showed high efficacy in our study. Rapamycin
and PP242 significantly inhibited tumour growth in HT-
1080 IDH mutant cells, where the productions of two
oncometabolites were also attenuated. High concentra-
tions of lactate and 2-HG exert tumour promoting
potential in a cooperative manner with the surveillance
of mTOR activity (e.g. 2-HG initiates DNA hypermethy-
lation and lactate fuels the bioenergetic process) [16, 52]
which can be present in the studied HT-1080 cells. Cer-
tainly, the above outlined network and its role in the poten-
tial metabolic symbiosis of the tissue microenvironment
could be regarded as an important phenomenon. However,
this cannot be denoted as an exclusive mechanism to main-
tain malignant phenotype of HT-1080 fibrosarcoma cells.
In addition, it has been published recently by E. Allen
et al. that inhibition of mTOR in combination can
disrupt the metabolic symbiosis of normoxic and hyp-
oxic cells in the developing targeted therapy resist-
ance [53]. This and our new results suggest that
targeting mTOR activity could have a promising potential
in different new combination treatments depending on
the metabolic phenotype of tumours.
These and our recent findings highlight that tumour
promoting mechanisms supported jointly by lactate and
2-HG oncometabolites – regulated by mTOR dependent
translational effects –, and especially the role of metabolic
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crossroads would be a promising approach to recognise a
set of molecular targets for anticancer therapy.
Conclusions
In conclusion, the mTORC1 inhibitor (rapamycin) showed
high efficacy in our models. The high mTOR activity re-
lated biological advances in tumour proliferation were
inhibited by rapamycin both in vitro and in vivo in the
studied heterozygous IDH1 mutant cells. Moreover, the al-
tered metabolic profile, the consequences of metabolic
adaptation to IDH1 mutation and to other tumourigenic
alterations (e.g. hyperactivated glycolytic pathway) such as
the high levels of two oncometabolites – 2-HG and lactate
– were also disrupted after the specific effect of rapamycin
treatment. Considering the role of these oncometabolites in
intracellular and microenvironmental regulatory networks
and their role in metabolic symbiosis it could be regarded
that rapamycin and other developing mTOR inhibitors
may have additional effects besides their anti-
proliferative effects in different tumours with character-
istic highly glycolytic phenotype, especially in case of
IDH1 mutation (such as AML, gliomas, chondrosar-
comas). Based on our new results we could suggest
targeting mTOR activity depending on the metabolic
besides molecular genetic phenotype of tumours to
increase the success of the future therapies.
Additional files
Additional file 1: Figure S1. Adding 2-HG, lactate did not influence
the anti-proliferative effect of rapamycin treatment in HT-1080 cells. The
in vitro anti-proliferative effect of rapamycin (50 ng/ml), Na-L-lactate
(5 mM) and D-2-HG (0.5 mM) combination treatments were studied
by Alamar Blue test after 48–72 h (the results of a representative
experiment n = 6, *:p < 0.05; Rapa = rapamycin, 2-HG = 2-hydroxyglutarate,
lac = lactate) (PDF 147 kb).
Additional file 2: Figure S2. The representative photos of p-mTOR,
p-S6, LDH-A and Gls immunostainings in HT-1080 xenograft tumours. The
expressions of p-mTOR, p-S6, LDH-A and Gls were studied in control and
Rapamune treated xenograft tumours (DAB-brown staining; magnification
400X) (PDF 209 kb).
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